Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer

被引：0
|
作者：
Manegold, C [1 ]
机构：
[1] Thoraxklin, Dept Internal Med & Oncol, D-69126 Heidelberg, Germany
来源：
SEMINARS IN ONCOLOGY | 1998年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 22
页数：5
相关论文
共 50 条
  • [21] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Manegold, C.
    Digumarti, R.
    Zukin, M.
    de Marinis, F.
    Mellerngaard, A.
    Gandara, D.
    Simms, L.
    Kaiser, C.
    Blatter, J.
    Gatzemeier, U.
    EJC SUPPLEMENTS, 2007, 5 (06): : 9 - 9
  • [22] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
  • [23] CONCURRENT CISPLATIN AND ETOPOSIDE WITH RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG-CANCER
    FRIESS, GG
    BAIKADI, M
    HARVEY, WH
    CANCER TREATMENT REPORTS, 1987, 71 (7-8): : 681 - 684
  • [24] Gemcitabine/vinorelbine/cisplatin in patients with advanced non-small cell lung cancer
    Doweik, L
    Pohl, G
    Malayeri, R
    Krajnik, G
    Minar, W
    Pirker, R
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 263 - 266
  • [25] A comparative study of combination chemotherapy with docetaxel/cisplatin versus gemcitabine/cisplatin for locally advanced non-small cell lung cancer
    El-Nashar, E
    LUNG CANCER, 2005, 49 : S243 - S243
  • [26] Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience
    Kim, JH
    Kim, SY
    Jung, KH
    Park, K
    Suh, CW
    Lim, HY
    Kim, YH
    Ryoo, BY
    Cho, EK
    Park, BJ
    Heo, DS
    LUNG CANCER, 2006, 52 (01) : 75 - 81
  • [27] Daily etoposide and cisplatin during thoracic radiotherapy for patients with locally advanced non-small cell lung cancer
    Bonner, JA
    Frytak, S
    Sloan, J
    Foote, RL
    Marks, RS
    Creagan, ET
    Richardson, RL
    Deschamps, C
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 312 - 312
  • [28] Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer
    Zwitter, Mayaz
    Kovac, Vijem
    Smrdel, Uros
    Strojan, Primoz
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) : 662 - 666
  • [29] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
  • [30] Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
    Sandler, AB
    Nemunaitis, J
    Denham, C
    von Pawel, J
    Cormier, Y
    Gatzemeier, U
    Mattson, K
    Manegold, C
    Palmer, MC
    Gregor, A
    Nguyen, B
    Niyikiza, C
    Einhorn, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 122 - 130
12345